Ari Green, MD

Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the development of potential remyelinating therapies and a recent trial of clemastine fumarate in patients with multiple sclerosis and chronic demyelinating optic neuropathy.


The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel .

Next Article:

High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS

Related Articles